FORMULASI DAN KARAKTERISASI NANOKARIER ARTEMISININ SERTA UJI AKTIVITAS ANTIMALARIA DARI SEDIAAN SECARA IN VITRO
Malaria treatment failure may be caused by the low bioavailability of the drugs and nonspecific drug targets to intracellular parasites. Artemisinin as a first-line treatment of malaria have limitations such as hydrophobicity, a short half-life and low bioavailability resulting in a low therapeuti...
Saved in:
| Main Author: | |
|---|---|
| Format: | Final Project |
| Language: | Indonesia |
| Online Access: | https://digilib.itb.ac.id/gdl/view/45383 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Institut Teknologi Bandung |
| Language: | Indonesia |
| Summary: | Malaria treatment failure may be caused by the low bioavailability of the drugs and nonspecific drug targets to intracellular parasites. Artemisinin as a first-line treatment of
malaria have limitations such as hydrophobicity, a short half-life and low bioavailability
resulting in a low therapeutic effectiveness. To improve the effectiveness of therapy,
antimalarial delivery systems need to be made selective towards red blood cells infected
with parasites. Because of it, nanocarrier consist of PLGA-poloxamer as artemisinin
delivery system was developed. Nanocarrier was developed with nanopresipitation method.
Nanocarrier formula was made by 5% poloxamer and varied concentration of PLGA.
Characterization of dosage form includes a physical characterization of particle size,
polydispersity index and a visual display. Chemical characterizations include encapsulation
efficiency and in vitro release test. Antimalarial activity test preparation performed on
culture conditions parasite Plasmodium falciparum 3D7 dominant phase of the ring.
Observations were made on the preparations layer of thick blood of the test results by
counting the number parasite in schizont phase and total asexual plasmodium. Nanocarrier
particle size increased with increasing concentrations of PLGA polymer. Encapsulation
efficiancy increased with increasing concentration of PLGA polymers. In vitro release test
at pH 7.4 and pH 5.5 showed no considerable difference in the testing of formulas with
different concentrations of PLGA. Antimalarial activity in vitro assay for formula PLGA 1
%, poloxamer 5% with artemisinin concentration 10 ppm, provided 43.65 ± 8.5284% of
inhibition percent. Artemisinin standard of 10 ppm without nanocarrier delivery systems
provided 27 833 ± 0.0288% (p <0.05) of percent inhibition. Nanocarrier formula of
artemisinin with artemisinin concentration of 10 ppm, 5% poloxamer, and 1.0% PLGA
give a better activity than the standard without nanocarrier system.
|
|---|